文献速递重症综合管理与镇静镇痛

组胺-2受体拮抗剂与质子泵抑制剂在重症成人中与谵妄发生的关联:一项回顾性队列研究

Association of Histamine-2 Blockers and Proton-Pump Inhibitors With Delirium Development in Critically Ill Adults: A Retrospective Cohort Study.
PubMed 文献 · Crit Care Explor · 2021-08-10
一句话结论在医疗ICU成人中,组胺-2受体拮抗剂比质子泵抑制剂与谵妄的关联更强(RR 1.36 vs 1.15),提示应激性溃疡预防药物选择可能影响谵妄负担。

这项回顾性队列研究利用美国北卡罗来纳大学医疗系统2015—2019年医疗ICU成人数据(n=6,645,排除同一住院期间同时使用H2RA和PPI者),以ICD编码算法识别谵妄,比较H2RA、PPI与两者均未使用者的谵妄关联。作者认为H2RA与谵妄的关联强于PPI,需前瞻性研究验证以PPI替代H2RA能否降低谵妄负担。

要点

  • H2RA与谵妄的关联强于PPI,提示应激性溃疡预防药物选择可能影响谵妄发生。
  • 该研究为回顾性观察性研究,仅提示关联而非因果,作者明确需前瞻性研究验证。
  • 研究排除同一住院期间同时使用H2RA和PPI的患者,结论不适用于联合用药人群。

适用人群与场景

  • 排除同一住院期间同时使用H2RA和PPI的患者。
  • 共6,645例,其中29%(n=1,899)接受机械通气,45%(n=3,022)年龄≥65岁,22%(n=1,487)在医疗ICU住院期间死亡。

诊断标准与关键阈值

  • 谵妄采用基于国际疾病分类(ICD)的算法识别。
  • 暴露分组:H2RA且无PPI(31%,n=2,057)、PPI且无H2RA(40%,n=2,648)、两者均未使用(对照组)。
  • 全文未提及谵妄评估量表名称、具体评分界值或启动/停止阈值。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或疗程。
  • 原文未提及谵妄预防或处理的流程性推荐。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性观察性队列研究,使用去标识数据库(美国北卡罗来纳大学医疗系统),单中心学术三级医疗ICU。
  • 样本量:6,645例医疗ICU成人;谵妄发生率46%(n=3,076)。
  • 关键次要终点与不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究(单中心)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:回顾性设计、单中心、使用ICD编码算法识别谵妄、仅提示关联而非因果,作者指出需前瞻性研究进一步阐明。

对床旁实践的改变

  • 在医疗ICU成人选择应激性溃疡预防药物时,可考虑H2RA与谵妄的关联强于PPI(RR 1.36 vs 1.15),但该证据为回顾性关联,不能据此确立因果或替代指征。
  • 该结论不适用于同一住院期间同时使用H2RA和PPI的患者(研究已排除)。
  • 常见陷阱:将观察性关联误读为PPI优于H2RA的确定性推荐;作者明确需前瞻性研究验证以PPI替代H2RA能否降低谵妄负担。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Histamine-2 receptor antagonists are commonly administered for stress ulcer prophylaxis in critically ill adults and may be associated with delirium development. We aimed to determine differential associations of histamine-2 receptor antagonist or proton-pump inhibitor administration with delirium development in patients admitted to a medical ICU.

DESIGN: Retrospective observational study using a deidentified database sourced from the University of North Carolina Health Care system. Participants were identified as having delirium utilizing an International Classification of Diseases-based algorithm. Associations among histamine-2 receptor antagonist, proton-pump inhibitor, or no medication administration and delirium were identified using relative risk. Multiple logistic regression was used to control for potential confounders including mechanical ventilation and age.

SETTING: Academic tertiary care medical ICU in the United States.

PATIENTS: Adults admitted to the University of North Carolina medical ICU from January 2015 to December 2019, excluding those on concurrent histamine-2 receptor antagonists and proton-pump inhibitors in the same encounter.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We identified 6,645 critically ill patients, of whom 29% (n = 1,899) received mechanical ventilation, 45% (n = 3,022) were 65 or older, and 22% (n = 1,487) died during their medical ICU encounter. Of the 6,645 patients, 31% (n = 2,057) received an histamine-2 receptor antagonist and no proton-pump inhibitors, 40% (n = 2,648) received a proton-pump inhibitor and no histamine-2 receptor antagonists, and 46% (n = 3,076) had delirium. The histamine-2 receptor antagonist group had a greater association with delirium than the proton-pump inhibitor group compared with controls receiving neither medication, after controlling for mechanical ventilation and age (risk ratio, 1.36; 1.25-1.47; p < 0.001) and (risk ratio, 1.15; 1.07-1.24; p < 0.001, respectively).

CONCLUSIONS: Histamine-2 receptor antagonists are more strongly associated with increased delirium than proton-pump inhibitors. Prospective studies are necessary to further elucidate this association and to determine if replacement of histamine-2 receptor antagonists with proton-pump inhibitors in ICUs decreases the burden of delirium in critically ill patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Shiddapur A, Kistler CE, Busby-Whitehead J, et al. Association of Histamine-2 Blockers and Proton-Pump Inhibitors With Delirium Development in Critically Ill Adults: A Retrospective Cohort Study. Crit Care Explor. 2021. PMID: 34396144. doi:10.1097/CCE.0000000000000507

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。